Please note that we are unable to disclose the full names of the companies due to their diversity.

Cheonan S University Hospital and Seoul Nowon U University Hospital are existing university hospitals. Starting in 2023, Company V, a distributor, is expected to register the product at the trauma center of Incheon G Hospital, a high-level general hospital, followed by ICU and NICU of Gangneung A Hospital, Gangbuk S Hospital, Seoul, and NICU of Wonju Y University K Hospital, a major hospital. The representative of Company V is the most excellent sales experience at Kabi, a major German company, and met at the Busan NICU Society exhibition in 2022, and asked for the domestic distribution rights of Anyfusion, saying that he was familiar with the problems of existing pumps and the experience of selling drug infusion pumps at Kabi.

Anyfusion Cylinder Pump is a new product with different technology, and with sales know-how to overcome the mistake points that occur due to nurses who are accustomed to the existing pump not accurately familiarizing with the new pump with different concepts, we made all nurses in all three shifts quickly adapt to the new pump, and made them realize the difference between real-time accuracy and FDA-recognized safety and effectiveness to prevent medical accidents caused by safety and effectiveness in the existing pump during the demo period, and found that the sales ability to lead to purchase with work efficiency and product competitiveness is excellent, so we gave the sales rights to Seoul and the metropolitan area.

By the first half of the year, all of the above hospitals will complete the registration of prescription codes, and if the use is stabilized, sales are expected to reach nearly 1 billion won per month. Gangneung A Hospital, a major hospital, has excellent demo results, so the medical engineering department recommended Seoul A Hospital, the main hospital, and is promoting the main hospital demo, and Gangbuk S Hospital gave a product demonstration and explanation to the head nurses of all departments of the hospital, and it was decided to start the demo of two departments immediately and do the demo of other departments in stages. Depending on the results, we expect to use Seoul S Hospital, the main hospital, and the use of the two major hospitals is expected to affect the activation of Anyfusion through the synergistic effect of using other hospitals nationwide.

All hospitals, including major hospitals in Korea, have used the products of 5-6 companies claiming to have overcome the problem of oil inside the pump, but all hospitals are disappointed with the same result and are looking for an alternative pump. Cylinder pumps have been confirmed by hospitals as pumps that have overcome these problems, improving treatment effects and increasing work efficiency, and are being confirmed as pumps that medical personnel are looking for through demos.

Overseas, under the premise of CE certification, Spain and Maldives presented specific purchasing details including ACPi system and cylinder pump. Italy, Saudi Arabia, and Algeria did not present relief sales estimates, but promised to purchase after certification, and sales of more than 50 billion won are expected in the second year, including domestic sales. Japan is still investigating the market.

Based on the reference obtained from the semi-auto ACPi system, ACPi Pro, a next-generation anti-cancer (injection) drug rapid dispensing equipment to be jointly developed with the Korea Institute of Machinery Research, is expected to reach sales of 100 billion won in the current year (3rd year) once development is completed and certification is completed. ACPi Pro is compact, can be used in existing BSCs, and can dispense 40 to 50 anticancer drugs per hour, as well as fill TPN and PCA balloons, and will be launched in cancer centers around the world to achieve trillion won in sales. We plan to raise 1-2 additional rounds of investment during the same period and pursue an IPO.

Thank you.